Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
Stable expression over 15 generations with rapid cell line development in just 3 months. Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
Predicted to enable calcium ion binding activity and patched binding activity. Acts upstream of or within several processes, including enteric nervous system development; intramembranous ossification; and swim bladder morphogenesis. Predicted to be located in several cellular components, including Golgi membrane; endoplasmic reticulum membrane; and extracellular region. Predicted to be active in extracellular space. Is expressed in several structures, including caudal fin skeleton; cranium; digestive system; pneumatic duct; and swim bladder bud. Human ortholog(s) of this gene implicated in acrocapitofemoral dysplasia; brachydactyly type A1; retinopathy of prematurity; and syndactyly type 1. Orthologous to human IHH (Indian hedgehog signaling molecule). [provided by Alliance of Genome Resources, Feb 2025]